{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:16:08Z","timestamp":1772165768504,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15346-8","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:56:34Z","timestamp":1764320194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy of nanoliposomal irinotecan in patients with advanced pancreatic cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Marie","family":"Decraecker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Le Joncour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Aurillac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u00eft\u00e9","family":"Sangnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Ducerf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Berroneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Laplace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Madau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Dumon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herve","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"23","key":"15346_CR1","first-page":"00148","volume":"S0016\u20135085","author":"EM Stoffel","year":"2023","unstructured":"Stoffel EM, Brand RE, Goggins M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology. 2023;S0016\u20135085(23):00148\u201358.","journal-title":"Gastroenterology"},{"key":"15346_CR2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","volume":"163","author":"LD Wood","year":"2022","unstructured":"Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163:386-402.e1.","journal-title":"Gastroenterology"},{"key":"15346_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pharmthera.2015.08.006","volume":"155","author":"C Neuzillet","year":"2015","unstructured":"Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, et al. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther. 2015;155:80\u2013104.","journal-title":"Pharmacol Ther"},{"key":"15346_CR4","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24:4846\u201361.","journal-title":"World J Gastroenterol"},{"key":"15346_CR5","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1053\/j.gastro.2022.07.072","volume":"163","author":"W Wu","year":"2022","unstructured":"Wu W. Early detection of pancreatic cancer: are we ready for prime time? Gastroenterology. 2022;163:1157\u20139.","journal-title":"Gastroenterology"},{"key":"15346_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejca.2022.06.042","volume":"174","author":"J Santucci","year":"2022","unstructured":"Santucci J, Tacey M, Thomson B, Michael M, Wong R, Shapiro J, et al. Impact of first-line FOLFIRINOX versus gemcitabine\/Nab-paclitaxel chemotherapy on survival in advanced pancreatic cancer: evidence from the prospective international multicentre PURPLE pancreatic cancer registry. Eur J Cancer. 2022;174:102\u201312.","journal-title":"Eur J Cancer"},{"key":"15346_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545\u201357.","journal-title":"Lancet"},{"key":"15346_CR8","doi-asserted-by":"publisher","first-page":"LBA661","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA661","volume":"41","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, Pazo-Cid R, Chandana SR, De La Fouchardiere C, et al. NAPOLI-3: a randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil\/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-na\u00efve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol. 2023;41:LBA661\u2013LBA661.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"15346_CR9","volume":"43","author":"GH Suhagiya","year":"2025","unstructured":"Suhagiya GH, Noori N, Masood M, Samreen I, Rahman H, Ahmed Z, et al. Efficacy of nanoliposomal irinotecan in metastatic pancreatic ductal adenocarcinoma: a meta-analysis of NAPOLI randomized clinical trials. J Clin Oncol. 2025;43(16_suppl):e16429.","journal-title":"J Clin Oncol"},{"key":"15346_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/JCMA.0000000000000650","volume":"85","author":"H-Y Yu","year":"2022","unstructured":"Yu H-Y, Lee C-Y, Lin L-G, Chao Y, Li C-P. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: a real-world experience. J Chin Med Assoc. 2022;85:42\u201350.","journal-title":"J Chin Med Assoc"},{"key":"15346_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081068","volume":"11","author":"L-T Chen","year":"2019","unstructured":"Chen L-T, Macarulla T, Blanc J-F, Mirakhur B, de Jong FA, Belanger B, et al. Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer. Cancers (Basel). 2019;11:1068.","journal-title":"Cancers (Basel)"},{"key":"15346_CR12","doi-asserted-by":"publisher","first-page":"9496","DOI":"10.1002\/cam4.5714","volume":"12","author":"KH Yu","year":"2023","unstructured":"Yu KH, Cockrum P, Surinach A, Lamarre N, Wang S, O\u2019Reilly EM. Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma. Cancer Med. 2023;12:9496\u2013505.","journal-title":"Cancer Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15346-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15346-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15346-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T20:03:44Z","timestamp":1767470624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15346-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15346"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15346-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4466955\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted closely with international guidance including the Good Clinical Practices and the Declaration of Helsinki. According to French national laws, the study was approved by a national Ethics Committee (CPP Est III, IDRCB 2023-A01665-40) and Competent Authority (ANSM) has been informed (NCT06006728, Registration Date: August 23, 2023). All alive participants have been provided comprehensive information notice regarding the purpose of the study, possible risks and expected benefits of the study, and participant's rights (voluntary participation and freedom to decline participation in the trial).All alive participants provided a Consent to Participate declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}